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Influenza A virus belongs to the Orthomyxoviridae family. It is an enveloped virus that 
contains a segmented, negative sense RNA genome. Influenza A viruses cause annual 
epidemics, occasional major pandemics, are a major cause of morbidity and mortality 
worldwide and have a significant financial impact on society.  Assembly and budding of new 
viral particles is a complex and multistep process involving several host and viral factors. 
Influenza viruses use lipid raft domains in the apical plasma membrane of polarized 
epithelial cells as sites of budding. Two viral glycoproteins, hemagglutinin and 
neuraminidase concentrate in lipid rafts, causing alterations in membrane curvature and 
initiation of the budding process. The matrix protein 1 (M1), which forms the inner structure 
of the virion, is then recruited to the site followed by incorporation of the viral 
ribonucleoproteins and the matrix protein 2 (M2). M1 can alter membrane curvature and 
progress budding whereas lipid raft-associated M2 stabilizes the site of budding, allowing for 
proper assembly of the virion. In the later stages of budding, M2 is localized to the neck of 
the budding virion at the lipid phase boundary where it causes negative membrane curvature 





Introduction to the influenza virus 
Influenza A virus causes annual epidemics, occasional pandemics and is a major cause of 
morbidity and mortality worldwide. The most severe influenza pandemic was a “Spanish” flu 
outbreak at the end of the First World War, between 1918 and 1919. In one year influenza 
virus caused the death of approximately 50 million people around the world, which was 
greater than the total number of war casualties [1]. The first pandemic in the 21st century 
arose in 2009 and was called “Swine” flu due to the origin of the virus. The “Swine” flu 
outbreak was associated with a low pathogenicity; however in the USA alone over 22 million 
people were infected [2]. Each influenza outbreak has an impact on society, not only in 
terms of mortality and morbidity but also in financial and economical terms.  
Influenza A virus is an enveloped virus with a negative-sense, single-stranded RNA genome 
and belongs to the Orthomyxoviridae family. The viral envelope is a host derived lipid 
membrane, which anchors three transmembrane-domain (TMD) containing proteins: 
hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2). HA is the most abundant 
envelope protein and has receptor binding and fusion activity whilst NA is a receptor-
destroying enzyme involved in viral release. M2 is a 97 amino acid, tetrameric, TMD-
containing protein, which is involved in both virus entry as well as assembly and budding. 
The TMD has ion channel activity which is essential for virus entry [3, 4] and the first 17 
amino acids of the cytoplasmic tail (CT) form an amphipathic helix (AH) that is essential for 
membrane budding [4, 5]. On the inside of the viral envelope there is a layer of matrix 
protein 1 (M1), which is the most abundant structural protein of the influenza virus. M1 
interacts with cytoplasmic tails of the surface glycoproteins [6, 7], with the ribonucleoprotein 
complexes (RNPs) [8] and plays a role in nuclear export, virus assembly and budding. The 
viral core contains eight RNPs each of which consist of a viral RNA (vRNA) segment bound 
to the nucleoprotein (NP) and associated with the three polymerase proteins: polymerase 
basic 1, polymerase basic 2 and polymerase acid [9].  
 
Initiation of virus budding                  
Influenza viruses assemble and bud from lipid raft domains in the apical plasma membrane 
of polarized epithelial cells [10-12]. Lipid rafts are ordered microdomains in the plasma 
membrane, enriched in sphingolipids and cholesterol [13]. The two viral glycoproteins, HA 
and NA, concentrate in, cluster and enlarge lipid raft domains, causing the initiation of virus 
budding [10-12]. In contrast, the third viral envelope protein, M2, is normally excluded from 
lipid rafts but can be recruited to the periphery during the process of virus budding, which 
may explain its low incorporation into virus particles [10-12]. 
Previous studies, using temperature sensitive mutants, have shown that HA is not required 
for virus assembly and budding from infected cells [14]. Subsequently, studies of NA-
deficient influenza viruses showed that the mutant virus assembles normally, though the 
budded virions are retained as large aggregates on the cell surface due to the absence of 
NA enzymatic activity [15]. This suggests that NA is not required for virus assembly and 
budding, but is essential for subsequent virion release. In contrast, research using a virus-
like particle (VLP) system, in which membrane budding is assessed following transfection 
and expression of individual viral proteins, has shown that, in presence of exogenous 
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neuraminidase, HA VLPs can be released from cells without need for expression of any 
other viral protein [10]. These results suggest that HA might be sufficient to induce positive 
Gaussian curvature (PGC) of the membrane and initiate the budding process. Nevertheless 
HA is not sufficient to complete in vivo budding in virus-infected cells, which may be 
prevented by assembly of other viral proteins, such as interactions of M1 with the CT of HA 
and recruitment of the vRNPs (reviewed in [16]). Correspondingly, expression of NA [17] and 
M2 [10] alone also caused release of VLPs, but neither are sufficient to complete in vivo 
budding. Moreover, co-expression of all three viral envelope proteins increased VLP release 
[10], which suggests that each viral envelope protein may play a role in altering membrane 
curvature and initiating virus  budding. Whilst each viral envelope protein can cause budding 
in a VLP system, all appear to be required for efficient virus budding. The reasons for the 
difference between in vitro VLP budding and in vivo virus budding are not known.  
 
 
Assembly of the virion 
The next step in the budding process is assembly of the virion. Newly synthesised RNP 
complexes and M1 are transported from the nucleus to the assembly site, following 
recruitment of M2 [16]. M1 is the most abundant protein among all viral particle components. 
It acts as a “bridge” between viral envelope proteins and the viral core; therefore it interacts 
with most of the viral proteins. Previous studies have shown that M1 is a major driving force 
in influenza budding and it is essential for VLP formation and when expressed alone 
assembles into VLPs [18]. However, recent studies suggest that M1 by itself fails to form 
VLPs and the interactions of M1 with the viral envelope proteins is essential for M1 plasma 
membrane localization and its incorporate into virions [19]. It has been shown that M1 
interacts with the CT and TMD of HA and NA and that both glycoproteins support the lipid 
raft association of M1 [7, 20]. Thus, M1 may also be able to alter membrane curvature during 
the progression of virus budding provided HA and NA have already initiated the budding 
event. Once properly targeted to the plasma membrane, M1 interacts with the inside layer of 
the lipid bilayer [21], which could cause bending of the plasma membrane, generating PGC 
and progressing viral bud formation [16]. This suggests that during virus budding, HA, NA 
and M1 all cooperate to alter membrane curvature and promote virion assembly.  
Later in the assembly process, the M2 protein is incorporated into the site of virus budding. 
When expressed alone, M2 is not associated with lipid rafts; however, when expressed with 
other viral proteins it is recruited to the raft periphery [5]. It is possible that the M2 interaction 
with M1 or HA alters M2 localization and facilitates M2 incorporation into virions [22]. In 
addition, it has been shown that the AH of M2 is able to insert into membranes and alter 
membrane curvature in a cholesterol dependent manner, a process that is necessary for 
membrane scission [23]. M2 causes a strong induction of negative Gaussian curvature 
(NGC) [23, 24] when cholesterol is below 17 molar %; however, in high levels of cholesterol 
the AH may not insert as deeply into the membrane, limiting the extent of membrane 
curvature [16, 23, 25]. Viral budding domains are enriched in cholesterol [13] and thus, the 
localization of M2 at these domains will prevent the strong elicitation NGC that could result in 
premature membrane scission.  
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Membrane scission and the completion of budding  
The final step in virus budding is membrane scission, which takes place at the neck of the 
budding virion. Recent results examining influenza virus budding and release show that the 
M2 protein is responsible for membrane scission [23]. During budding, M2 localizes to the 
boundary between lipid-ordered (raft) and lipid-disordered domains. Viral proteins clustered 
in lipid raft budding domains are progressively incorporated into the virion.  As M2 is located 
at the periphery of the budding domain, this will concentrate M2 at the neck of budding virus 
at the boundary between the lipid-ordered virus and the lipid-disordered bulk plasma 
membrane. In this lower cholesterol environment, the M2 AH may insert deeper into the 
membrane and cause further alterations in membrane curvature. Strong induction of NGC in 
the neck of budding virion may constrict the membrane neck below 10 nm, enabling 
spontaneous membrane scission to occur and triggering the release of new influenza viruses 
[23]. These studies also showed that mutation of the AH of M2 blocks membrane scission 
and release of the virus. Mutant virions were not able to complete budding and displayed a 
“beads on a string” morphology indicative of a scission defect [23].  
Recent studies, using solid-state NMR spectroscopy confirmed that M2 amphipathic helix 
alters membrane curvature [26]. The extent of M2-induced membrane curvature was 
affected by membrane cholesterol [25, 26], which is consistent with previous observations of 
full-length protein in large unilamellar vesicles [23]. It was also shown that the M2 AH binds 
to lipid domains with high radii of curvature such as would be found at the neck of the 
budding virus and that this binding causes significant disruption of lipid head group packing 
[26]. Additionally, research using small angle X-ray scattering has confirmed that M2 is able 
to generate NGC in lipid membranes [24]. Consistent with previous results, reduction in the 
hydrophobicity of the AH by amino acid substitution resulted in inhibition of M2’s ability to 
alter membrane curvature [24]. Although the M2 AH was necessary and sufficient to 
generate NGC, the presence of the M2 TMD enhanced the M2 AH-induction of NGC, 
suggesting that the TMD may affect AH activity, facilitating alteration of membrane curvature 
[24]. It has been shown, that mutation of the CT of the M2 protein causes a significant 
reduction in budding efficiency, but does not completely inhibit virus release [22, 27]. This 
suggests that other cellular factors, such as Rab11 [28], may be involved in the budding 
process or may orchestrate a redundant scission mechanism. 
 
Summary 
Influenza virus assembly and budding are complex, multi-step processes involving many 
host and viral factors. The exact model of assembly and budding has not been elucidated 
despite many years of research. One of the main difficulties has been the presence of 
conflicting results derived from comparing VLP budding and virus budding. It has been 
shown that viral envelope proteins and the M1 protein can cause VLP budding when 
expressed alone [10, 17, 18, 23]. In contrast, the expression of all viral proteins is essential 
for efficient virus budding from infected cells [14, 15]. The reasons for the difference between 
VLP and virus budding are not fully understood; however, it is probable that in infected cells 
the presence of each additional viral protein may sequentially alter protein localization, 
interactions and membrane curvature, causing significant differences in the process of 
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assembly and budding. It is not clear what the major driving force is for influenza virus 
assembly and budding.  
An overall model of influenza virus assembly and budding suggest that several virus proteins 
mediate the process, rather than a single one. HA and NA are transported to lipid raft 
domains, where they concentrate. This may cause alteration of membrane curvature and 
initiation of the budding event. M1 may then be recruited to the site by interacting with the 
cytoplasmic tails of HA and NA. Membrane bound M1 can polymerize and form the inner 
structure of the virion, excluding host proteins from the budding site. Additionally, M1 may 
alter membrane curvature to progress the budding event; however, M1-mediated recruitment 
of vRNPs or M2 may temporally block completion of budding process. Recruitment of M2 to 
the lipid-ordered budding site may cause stabilization necessary to allow for proper 
assembly of the virion before the completion of membrane scission. Following assembly, M2 
will be localized to the neck of budding virion, at the lipid phase boundary, where insertion of 
the M2 AH can cause NGC, leading to scission and virion release [23]. It has been proposed 
that M2 AH-alternations of membrane curvature may enable membrane scission through the 
alteration of line tension between the two lipid phases and through lipid packing defects 
caused by insertion of the AH into the inner leaflet of the membrane bilayer [23]. Recent 
studies, have confirmed that the AH of the M2 protein alters membrane curvature in a 
manner that is affected by the specific lipid environment [24, 26], however the exact 
molecular mechanisms that regulate the alteration of membrane curvature during influenza 
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